Trials have suggested that SaNOtize's spray killed 99.9% of the coronaviruses that cause COVID-19.
Early-stage clinical trials of a spray produced by SaNOtize Research & Development Corp. have found that the product is effective in killing coronavirus particles. The trials in Utah, Canada, and the United Kingdom of a nasal spray produced by SaNOtize Research & Development Corp. (SaNOtize) have found to have lessened the COVID-19 viral load in infected patients. In the Times of Israel report, the Israeli co-founder of SaNOrize, Dr. Gilly Regev, said that the nasal spray is similar to hand sanitizer. It is used in the nose to create a solid barrier in the nasal entrances to stop the virus in its tracks. Viral load refers to the levels of a virus found in someone's bloodstream.
On April 22, 2020, SaNOtize announced that tests conducted by the Institute for Antiviral Research at Utah State University confirm that SaNOtize's Nitric Oxide Releasing Solution (NORSTM) had killed off more than 99.9 percent of the COVID-19 virus cells.
On March 15, 2021, the U.K. announced the nasal spray's Phase II trial results. Seventy-nine confirmed COVID-19 cases were evaluated in the trial, and it was proved that the level of high viral loads was significantly reduced through SaNOtize's immediate treatment. In the first 24 hours, the viral log reduction was about 95 percent and dropped by more than 99 percent within 72 hours.
The U.K. and Canadian trials of over 7,000 patients recorded no adverse side effects. Moreover, the U.K. trial results confirm the information collected from independent lab tests at Utah State University's Antiviral Research Institute and Canadian trials. Israel and New Zealand have granted interim approval for the nasal spray's sale.
A press release from Royal Holloway University, who were involved in the trials of the spray, said that it could be effective in treating mild to moderate cases of COVID-19: "The strategy is to use the Nitric Oxide spray as a multi-stage defense against infection and to provide an effective treatment for mild and moderate cases with the goal of preventing severe inflammatory response and infection of the lungs."
It added: "Scientists believe the coronavirus is transmitted via airborne droplets to the mucous membranes in the nose, where it is replicated during a three-day incubation period, damaging the nasal mucosa cells, and is then carried in nasal secretions to the lower respiratory tract, leading to the danger of fatal viral pneumonia."
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.